- Title
- The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
- Creator
- Peters, S.; Clézardin, P.; Márquez-Rodas, I.; Niepel, D.; Gedye, C.
- Relation
- Clinical and Translational Oncology Vol. 21, Issue 8, p. 977-991
- Publisher Link
- http://dx.doi.org/10.1007/s12094-018-02023-5
- Publisher
- Springer
- Resource Type
- journal article
- Date
- 2019
- Description
- Drug repurposing offers advantages over traditional drug development in terms of cost, speed and improved patient outcomes. The receptor activator of nuclear factor kappa B (RANK) ligand (RANKL) inhibitor denosumab is approved for the prevention of skeletal-related events in patients with advanced malignancies involving bone, including solid tumours and multiple myeloma. Following improved understanding of the role of RANK/RANKL in cancer biology, denosumab has already been repurposed as a treatment for giant cell tumour of bone. Here, we review the role of RANK/RANKL in tumourigenesis, including effects on tumour initiation, progression and metastasis and consider the impact of RANK/RANKL on tumour immunology and immune evasion. Finally, we look briefly at ongoing trials and future opportunities for therapeutic synergy when combining denosumab with anti-cancer agents such as immune checkpoint inhibitors.
- Subject
- checkpoint; denosumab; immunotherapy; osteoprotegerin; RANK; RANKL
- Identifier
- http://hdl.handle.net/1959.13/1451654
- Identifier
- uon:44240
- Identifier
- ISSN:1699-048X
- Rights
- This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Language
- eng
- Full Text
- Reviewed
- Hits: 1945
- Visitors: 2003
- Downloads: 65
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 6 MB | Adobe Acrobat PDF | View Details Download |